• Publications
  • Influence
Health Utilities Using the EQ-5D in Studies of Cancer
Cancer is one of the most frequent disease-specific applications of the EQ-5D. The objective of this review was to summarise evidence to support the validity and reliability of the EQ-5D in cancer,Expand
  • 195
  • 9
  • PDF
Use of a preference-based measure of health (EQ-5D) in COPD and asthma.
BACKGROUND EQ-5D is a generic preference-based measure of health that can help to understand the impact of asthma and chronic obstructive pulmonary disease (COPD). The purpose of this paper was toExpand
  • 121
  • 8
Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
BACKGROUND To date, there is mixed evidence on the safety and effectiveness of tiotropium. Our objective was to evaluate the comparative effectiveness of regimens containing tiotropium bromide vsExpand
  • 54
  • 5
  • PDF
Disease-specific patient reported outcome tools for systemic lupus erythematosus.
PURPOSE Systemic lupus erythematosus (SLE) can significantly affect both health and non-health-related quality of life (HRQOL and non-HRQOL). However, of the existent published patient-reportedExpand
  • 84
  • 3
Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study.
The utility-based approach to health measurement, exemplified by EQ-5D and Health Utilities Index (HUI), has been challenged on a theoretical basis, but the statistical implications of such anExpand
  • 14
  • 3
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via
ABSTRACT Objectives: People with severe hemophilia suffer from frequent intra-articular hemorrhages, leading to pain, swelling, reduced flexion, and arthropathy. Elective orthopedic surgery usingExpand
  • 31
Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg−1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research
Summary.  Recombinant factor VIIa (rFVIIa) is a well‐established treatment for managing bleeding episodes in individuals with congenital haemophilia complicated by alloantibody inhibitors (CHwI). TheExpand
  • 12